Kazia Therapeutics Says Paxalisib Phase 1b Data In Six Evaluable Stage IV Triple-Negative Breast Cancer Patients Showed 83% Objective Response Rate, No Treatment-Related Serious Adverse Events

Benzinga Newsdesk www.benzinga.com Positive 68.3%

Neg 0% Neu 0% Pos 68.3%

Comments

No comments yet. Be the first!